The estimated Net Worth of Sanj K Patel is at least $15.8 million dollars as of 1 September 2024. Mr. Patel owns over 23,043 units of Kiniksa Pharmaceuticals International Plc stock worth over $2,013,600 and over the last 10 years he sold KNSA stock worth over $9,002,395. In addition, he makes $4,765,670 as Chairman of the Board et Chief Executive Officer at Kiniksa Pharmaceuticals International Plc.
Sanjiv has made over 15 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 23,043 units of KNSA stock worth $560,867 on 1 September 2024.
The largest trade he's ever made was selling 251,572 units of Kiniksa Pharmaceuticals International Plc stock on 9 October 2020 worth over $5,288,043. On average, Sanjiv trades about 21,145 units every 51 days since 2014. As of 1 September 2024 he still owns at least 82,728 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr. Patel stock trades at the bottom of the page.
Sanjiv K. (Sanj) Patel is Chairman of the Board, Chief Executive Officer of the Company. In June 2008, Mr. Patel formed Synageva, a biotechnology company focused on rare diseases, where he served as President and Chief Executive Officer and was a member of its board of directors until Synageva's sale to Alexion Pharmaceuticals, Inc. ("Alexion"), in June 2015. Prior to Synageva, Mr. Patel held various roles at Genzyme Corporation ("Genzyme") from 1999 to 2008, most recently as head of U.S. Sales, Marketing and Commercial Operations for the Genzyme Therapeutics franchise. Mr. Patel previously served as a member of the boards of directors of Syros Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., and Intercept Pharmaceuticals, Inc. He is also the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic organization that supports charities for patients with rare and devastating diseases. Mr. Patel holds a B.Sc. with Honors from the University of the South Bank, London and completed his management and business studies at Ealing College, London and his Pharmacology research program at the Wellcome Foundation.
As the Chairman of the Board et Chief Executive Officer of Kiniksa Pharmaceuticals International Plc, the total compensation of Sanjiv Patel at Kiniksa Pharmaceuticals International Plc is $4,765,670. There are no executives at Kiniksa Pharmaceuticals International Plc getting paid more.
Sanjiv Patel is 50, he's been the Chairman of the Board et Chief Executive Officer of Kiniksa Pharmaceuticals International Plc since 2015. There are 10 older and 3 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
Sanj's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... et Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include: